BC Week In Review | Jun 11, 2012
Clinical News

CBP501: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 65 chemotherapy-naïve patients with unresectable MPM showed that 25 mg/m 2 IV CBP501 plus cisplatin and pemetrexed on day 1 of a 21-day cycle met...
BC Extra | Jun 5, 2012
Clinical News

CanBas' CBP501 meets mesothelioma endpoint

CanBas Co. Ltd. (Tokyo:4575) said CBP501 plus cisplatin and pemetrexed met the primary endpoint of a progression-free survival rate greater than 55% at four months in a Phase II trial to treat malignant pleural mesothelioma...
BC Week In Review | Jan 16, 2012
Clinical News

CBP501 regulatory update

FDA granted Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas expects to complete a Phase II trial evaluating the product plus cisplatin and pemetrexed for first-line treatment...
BC Week In Review | Nov 7, 2011
Clinical News

CBP501: Completed Phase II enrollment

CanBas completed enrollment of 63 chemotherapy-naïve patients in an open-label, international Phase II trial comparing IV CBP501 plus cisplatin and pemetrexed vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta...
BC Week In Review | Nov 7, 2011
Clinical News

CBP501: Completed Phase II enrollment

CanBas completed enrollment of 192 patients in an open-label, international Phase II trial comparing 25 mg/m 2 IV CBP501 in combination with 500 mg/m 2 IV pemetrexed and 75 mg/m 2 IV cisplatin given on...
BioCentury | Sep 28, 2009
Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
BC Extra | Sep 22, 2009
Financial News

D. Western planning IPO

D. Western Therapeutics Institute Inc. (Nagoyashi, Japan) is planning to sell 3 million shares in an IPO. The offering is being underwritten by Nomura; Mitsubishi UFJ; Takagi; SBI Securities; Tokai Tokyo; Mizuho; Nikko Citigroup; Ichiyoshi;...
BC Week In Review | Dec 15, 2008
Clinical News

CBP501: Phase II started

The partners began an open-label, international Phase II trial to evaluate cisplatin and pemetrexed with or with intravenous CBP501 in 65 patients. Takeda has exclusive rights to the product outside of the U.S., where the...
BioCentury | Apr 14, 2008
Strategy

Takeda cancer deals

Takeda cancer deals Date Partner/Acquisition Description Terms 4/10/08 (A) Millennium (NASDAQ:MLNM) Takeda to acquire Millennium; deal is expected to strengthen its global oncology portfolio and expand its global gastrointestinal portfolio ~$8.8B in cash 3/31/08 Cell...
BioCentury | Apr 14, 2008
Strategy

Cancer & GI pipeline

Cancer & GI pipeline Cancer Product Description Indication Status Originator Leuprorelin acetate (TAP-144SR) (A) 6-month depot formulation of leuprorelin, a luteinizing hormone releasing hormone(LHRH) agonist Prostate cancer Under review in EU Takeda Velcade (A) Small...
Items per page:
1 - 10 of 13